中文 | EN
/
home logo
股票简称：近岸蛋白
股票代码：688137
Top search:
New Products
Apply for Sample
Citations
Apply for scholarship
Authorized Distributors
Resource Download
Featured Products
More
Trusted choice of world-renowned scientific research institutes and pharmaceutical companies
Molecular Diagnostic Enzymes and Reagents
Manufactured under ISO 13485:2016 certification. Customized specifications & formulation, assisted lyophilized products development.
Target Proteins For Antibody Drug Discovery and Development
High Quality，Great Reliability
Solutions for circRNA raw material
Full range, GMP grade/scientific research grade
GMP-grade cytokines/antibodies
Enable cell therapy
Products
More
Dedicated & professional. Choose cost-effective products to save time and cost
product-list-preview
mRNA Vaccine & Drug Enzymes
product-list-preview
Gene and Cell Therapy
product-list-preview
Cytokines
product-list-preview
Target Proteins
product-list-preview
Biosimilar Reference Antibodies
product-list-preview
Molecular Research
product-list-preview
Molecular Diagnosis
product-list-preview
Immuno-Diagnostics Reagents
product-list-preview
Virus Related Products
Services
More
Novoprotein provides a full set of technical services related to recombinant protein preparation to solve your R&D and production problems
Vaccine Development Service
  • Vaccine development service
 
mRNA Synthesis Custom Service

  • mRNA synthesis custom service

Antibody Development Service

  • Antibody development

 
Protein Modification and Labeling Service

  • Protein modification and labeling

MHC-I-peptide Complex Service

  • Preparation of MHC-I-peptide complex protein

 
VLP Protein Service

  • Mature virus-like particle assembly process and rich experience platform

  • Assemble active virion-like structures in vitro VLP particles are widely used as a developable form of vaccine

News and Activities
More
See industry trends and support the development of Novoprotein
Chicago | Novoprotein Invites You to Participate in ADLM 2024
2024-07-26
Vitalgen and Novoprotein enter into a strategic collaboration to promote the commercial application of AaCas12bMax, a clinical-grade "0 off-target" gene editor
2024-07-22
Novoprotein's Stem Cell and Organoid R&D Solutions a Big Hit with Researchers Worldwide at ISSCR 2024
2024-07-12
Germany | NOVOPROTEIN Invites You to Participate in ISSCR 2024
2024-07-05
Novoprotein Wins "Top 10 Excellent Suppliers of Local Raw Materials for Bio-Innovative Pharmaceuticals" Award
2024-06-17
Novoprotein shines again in CGT field and won the award of "Star of CGT field raw material reagent"
2024-05-24
Novoprotein has been awarded "Asia Pacific CGT Industry Star 2024 Raw Material Provider of the Year" for the second consecutive year.
2024-04-03
Optimists Go Forward: The "Top 10" Keywords for Novoprotein in 2023
2024-01-01